Alnylam Pharma (ALNY) AI Stock Analysis

• Market Cap: $60.87B
• Dividend Yield: N/A
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): 1916.6
• Beta (1Y): 0.95
• Revenue Growth: 53.24%
• EPS Growth: N/A
• Country: US
• Employees: 2,230
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.84
• Shares Outstanding: 132,113,820
• 10 Day Avg. Volume: 855,438
• 30 Day Avg. Volume: 1,078,849
• PEG Ratio: 2.84
• Price to Book (P/B): 447.73
• Price to Sales (P/S): 13.36
• P/FCF Ratio: -705.29
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 19.53
• Enterprise Value/Gross Profit: 23.25
• Enterprise Value/Ebitda: 336.00
• 1Y Price Target: $504.24
• Price Target Upside: 9.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 23
• EPS Forecast (FY): 2.26
• Revenue Forecast (FY): $3.72B

• Rating: 57 Neutral
• Price Target: $465.00 ▲(0.92% Upside)

Alnylam Pharma's overall stock score is driven by strong revenue growth and positive earnings call sentiment, reflecting confidence in future performance. However, high leverage, cash flow challenges, and a negative P/E ratio weigh down the score. Technical indicators suggest mixed momentum, with short-term bearish signals but no overbought conditions.

Positive Factors

Revenue Growth

Strong revenue growth driven by successful product launches indicates robust market demand and enhances long-term financial stability.

Product Launch Success

The successful launch of AMVUTTRA demonstrates Alnylam's effective commercialization strategy, supporting sustained revenue growth and market expansion.

Global Expansion

Regulatory approvals in key markets enhance Alnylam's global reach, allowing access to a larger patient base and supporting long-term growth.

Negative Factors

High Leverage

High leverage can strain financial resources, limiting flexibility and increasing risk, potentially impacting long-term financial health.

Negative Profitability

Persistent negative profitability despite efficient production indicates challenges in cost management, affecting long-term financial sustainability.

Decreased Collaboration Revenue

Reduced collaboration revenue may limit funding for R&D and strategic initiatives, impacting future growth and innovation potential.

Alnylam Pharma Business Overview & Revenue Model

Company Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies based on RNA interference (RNAi). Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam is a leader in the RNAi therapeutics sector, aiming to treat a range of diseases by silencing specific genes. The company's core products include Onpattro (patisiran), which is approved for the treatment of hereditary transthyretin-mediated amyloidosis, and several other investigational therapies targeting various genetic disorders and conditions.

How the Company Makes Money

Alnylam Pharmaceuticals generates revenue primarily through the sale of its approved therapies, most notably Onpattro. The company also earns income through collaborations and partnerships with other pharmaceutical companies, which may include upfront payments, milestone payments based on development progress, and royalties on product sales. Notable partnerships with companies like Sanofi and Regeneron have further enhanced its revenue streams, allowing for shared development costs and increased market reach. Additionally, Alnylam may receive government grants and funding for research projects, contributing to its earnings.

Alnylam Pharma Financial Statement Overview

Summary

Alnylam Pharma shows strong revenue growth and improving profitability metrics, but faces challenges with high leverage and cash flow management. The company is on a positive trajectory with improving margins, yet needs to address its debt levels and enhance cash flow generation to ensure long-term financial stability.

Income Statement

Alnylam Pharma has shown significant revenue growth with a 30.39% increase in TTM, indicating strong sales momentum. The gross profit margin is healthy at 83.72% in 2022, but the net profit margin remains low at 1.36% in TTM, reflecting challenges in achieving profitability. The EBIT and EBITDA margins have improved but are still negative, suggesting ongoing operational inefficiencies.

Balance Sheet

The company's balance sheet shows a high debt-to-equity ratio of 5.59 in TTM, indicating significant leverage and potential financial risk. However, the return on equity has improved to 26.13% in TTM, suggesting better utilization of equity. The equity ratio is low, highlighting a reliance on debt financing.

Cash Flow

Cash flow analysis reveals a negative free cash flow growth rate of -524.98% in TTM, indicating cash flow challenges. The operating cash flow to net income ratio is low at 0.17, suggesting limited cash generation from operations relative to net income. The free cash flow to net income ratio is relatively strong at 0.83, indicating some ability to convert income into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.21B	2.25B	1.83B	1.04B	844.29M	492.85M
Gross Profit	2.70B	1.92B	1.52B	868.60M	704.14M	414.80M
EBITDA	186.55M	-178.85M	-258.24M	-926.56M	-661.56M	-736.33M
Net Income	43.56M	-278.16M	-440.24M	-1.13B	-852.82M	-858.28M
Balance Sheet
Total Assets	4.85B	4.24B	3.83B	3.55B	3.64B	3.41B
Cash, Cash Equivalents and Short-Term Investments	2.72B	2.69B	2.44B	2.19B	2.44B	1.87B
Total Debt	2.77B	2.74B	1.31B	1.32B	997.59M	521.19M
Total Liabilities	4.62B	4.17B	4.05B	3.70B	3.06B	2.39B
Stockholders Equity	233.89M	67.09M	-220.64M	-158.22M	588.20M	1.02B
Cash Flow
Free Cash Flow	221.36M	-42.59M	41.95M	-613.33M	-718.07M	-685.32M
Operating Cash Flow	265.86M	-8.31M	104.16M	-541.27M	-641.69M	-614.96M
Investing Cash Flow	420.58M	-116.84M	-336.35M	169.35M	-273.30M	-435.52M
Financing Cash Flow	-319.51M	294.16M	172.13M	425.75M	1.25B	994.98M

Alnylam Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 460.76
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALNY, the sentiment is Positive. The current price of 460.76 is above the 20-day moving average (MA) of 453.88, above the 50-day MA of 458.36, and above the 200-day MA of 347.49, indicating a bullish trend. The MACD of -0.73 indicates Negative momentum. The RSI at 53.35 is Neutral, neither overbought nor oversold. The STOCH value of 84.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALNY.

Alnylam Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INCY	81 Outperform	$19.89B	17.00	30.39%	―	18.09%	3563.21%
ARGX	79 Outperform	$56.57B	42.96	24.75%	―	89.58%	―
VRTX	78 Outperform	$110.12B	30.69	22.31%	―	10.53%	―
GMAB	76 Outperform	$18.85B	12.77	28.20%	―	24.98%	127.06%
ALNY	57 Neutral	$60.87B	1,916.64	32.73%	―	53.24%	―
BNTX	53 Neutral	$24.69B	―	-2.94%	―	7.04%	-25.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Alnylam Pharma Corporate Events

Alnylam Pharmaceuticals Reports Strong Q3 2025 Growth

Alnylam Pharmaceuticals, Inc. is a leading biotechnology company specializing in RNA interference (RNAi) therapeutics, focusing on innovative treatments for rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts.

Alnylam’s ZENITH Study: A New Horizon in Cardiovascular Treatment

Alnylam Pharmaceuticals is conducting a pivotal Phase 3 clinical study titled ZENITH to evaluate the efficacy and safety of zilebesiran in patients with hypertension not adequately controlled and who have either established cardiovascular disease or are at high risk for cardiovascular disease. The study aims to determine if zilebesiran, when added to standard care, can reduce major adverse cardiovascular events such as cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events.

Alnylam Pharmaceuticals Completes Phase 1 Study of ALN-TTRSC04: Market Implications

Alnylam Pharmaceuticals recently completed a Phase 1 study titled A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneously Administered ALN-TTRSC04 in Healthy Subjects. The study aimed to assess the safety and tolerability of ALN-TTRSC04, a potential treatment for Transthyretin-Mediated Amyloidosis, by administering single ascending doses to healthy participants.

Alnylam and Regeneron Join Forces in Promising Alzheimer’s Study

Study Overview: Alnylam Pharmaceuticals, in collaboration with Regeneron Pharmaceuticals, is conducting a Phase 1 study titled A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer’s Disease. The study aims to assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of ALN-5288 in patients with Alzheimer’s Disease, marking a significant step in addressing this challenging condition.

Alnylam Pharma Secures $500M Credit Agreement

On September 30, 2025, Alnylam Pharmaceuticals entered into a Credit Agreement with Bank of America and other lenders, securing a $500 million revolving line of credit. This agreement, which includes a $150 million letter of credit sublimit, allows Alnylam to use the funds for working capital and general corporate purposes. The credit facility is subject to various financial covenants, including maintaining specific leverage and interest coverage ratios, and is secured by the company’s assets. The maturity date for the credit facility is September 30, 2030, with provisions for early maturity under certain conditions.

The most recent analyst rating on (ALNY) stock is a Buy with a $471.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.

Alnylam Pharmaceuticals Completes Phase 1 Study of ALN-AGT01 RVR

Alnylam Pharmaceuticals recently completed a Phase 1 clinical study titled A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-AGT01 RVR in Adult Healthy Volunteers. The study aimed to assess the safety, tolerability, and pharmacokinetics of ALN-AGT01 RVR, a new drug candidate, in healthy adults. This research is significant as it lays the groundwork for future clinical trials and potential therapeutic applications.

Alnylam Pharma Executes Note Repurchase Transactions

Alnylam Pharma has engaged in financial maneuvers involving convertible senior notes. The company offered and sold notes to initial purchasers under exemptions from registration, with potential issuance of up to 1,381,483 shares of common stock upon conversion. Concurrently, Alnylam executed note repurchase transactions, buying back approximately $637.8 million of its 1.00% convertible senior notes due 2027 for around $1,105.8 million, influenced by market conditions.

The most recent analyst rating on (ALNY) stock is a Buy with a $515.05 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.

Alnylam Pharma Announces $500M Convertible Notes Offering

On September 8, 2025, Alnylam Pharmaceuticals announced a proposed private offering of $500 million in convertible senior notes due 2028, targeting qualified institutional buyers. The offering aims to support capped call transactions and repurchase existing notes, potentially impacting Alnylam’s stock market activity and conversion price. The company plans to use the proceeds for these financial strategies and general corporate purposes, with implications for its market positioning and stakeholder interests.

The most recent analyst rating on (ALNY) stock is a Buy with a $470.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.

Alnylam’s TRITON-CM Study: A Potential Breakthrough in Cardiomyopathy Treatment

Alnylam Pharmaceuticals is conducting a Phase 3 study titled ‘TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.’ The study aims to assess the effectiveness of nucresiran in reducing mortality and cardiovascular events in patients suffering from this condition, while also evaluating its impact on patients’ health status and quality of life.

Alnylam’s Vutrisiran Study Advances in Treating Rare Cardiomyopathy

Study Overview: Alnylam Pharmaceuticals is conducting an open-label extension study titled An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy. The study aims to gather data on the safety, efficacy, and pharmacodynamics of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy, either continuing or switching from patisiran. This research is significant as it addresses a critical need for effective treatments for this rare condition.

Alnylam’s Phase 2 CAA Study: A Potential Game-Changer in Neurological Treatments

Study Overview: Alnylam Pharmaceuticals is conducting a Phase 2 trial titled ‘A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA).’ The study aims to assess the impact of ALN-APP on CAA disease progression and evaluate its safety and tolerability in patients with sporadic and Dutch-type CAA.

Alnylam Pharmaceuticals’ ELEVATE Study: A Closer Look at AHP Management

Study Overview: Alnylam Pharmaceuticals is conducting a study titled ‘ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP).’ The study aims to understand the natural history and real-world management of AHP, as well as evaluate the safety and effectiveness of givosiran and other approved therapies. This research is significant as it seeks to enhance the understanding of AHP and improve treatment strategies.

Alnylam’s ALN-APP Study: A Promising Step in Alzheimer’s Treatment

Alnylam Pharmaceuticals is conducting a clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients With Early-onset Alzheimer’s Disease (EOAD)’. The study aims to assess the safety and tolerability of ALN-APP, a drug administered via intrathecal injection, in patients with EOAD. This research is significant as it explores potential treatments for a challenging condition.

Alnylam’s NeuroFeeL Study: A Potential Game-Changer for hATTR Amyloidosis

Study Overview: Alnylam Pharmaceuticals is conducting an observational study titled NeuroFeeL Study to evaluate Neurofilament Light Chain (NfL) levels as a biomarker in asymptomatic carriers of Transthyretin (TTR) gene variants and patients with hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy. The study aims to assess NfL’s potential for diagnosing, detecting disease onset, monitoring progression, and evaluating treatment response, which could significantly enhance patient management and outcomes.

Alnylam’s ConTTRibute Study: A Closer Look at Real-World Impact on ATTR Amyloidosis

Alnylam Pharmaceuticals is conducting a global observational study titled ‘ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)’. The study aims to describe the epidemiological and clinical characteristics, natural history, and real-world management of ATTR amyloidosis patients. It also seeks to assess the safety and effectiveness of patisiran and vutrisiran in routine clinical practice, and to observe disease progression in pre-symptomatic carriers of a TTR variant.

Alnylam’s ALN-HTT02 Study: A Potential Game-Changer for Huntington’s Disease

Study Overview: Alnylam Pharmaceuticals is conducting a study titled A Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered Single Ascending Doses of ALN-HTT02 in Adult Patients With Huntington’s Disease. The study aims to assess the safety and effectiveness of ALN-HTT02, a potential treatment for Huntington’s Disease, a progressive brain disorder.

Alnylam’s Patisiran-LNP Study: Key Insights for Investors

Alnylam Pharmaceuticals is conducting a study titled ‘Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program’ to assess pregnancy outcomes in women exposed to patisiran-LNP. This study aims to gather data on pregnancy complications and fetal/neonatal outcomes, providing crucial insights into the safety of this treatment during pregnancy.

Alnylam’s Innovative Approach in Liver Cancer Treatment: A Phase 1 Study Update

Study Overview: Alnylam Pharmaceuticals is conducting a Phase 1 study titled A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma. The study aims to assess the safety, tolerability, and antitumor activity of ALN-BCAT, both alone and with pembrolizumab, in patients with advanced stages of liver cancer. This research is significant as it explores new treatment avenues for a challenging condition.

Alnylam’s Vutrisiran Study: A Potential Game-Changer for ATTR Amyloidosis Treatment?

Alnylam Pharmaceuticals is conducting a study titled ‘An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.’ The study aims to gather data on the safety, efficacy, and pharmacodynamics of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy, focusing on those continuing or switching from patisiran.

Alnylam’s Vutrisiran Study: A Potential Game-Changer for Cardiomyopathy Treatment

Study Overview: Alnylam Pharmaceuticals is conducting an open-label extension study titled An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy. The study aims to gather safety, efficacy, and pharmacodynamic data on vutrisiran for patients with transthyretin amyloidosis with cardiomyopathy, either continuing from previous use or switching from patisiran. This research is significant as it seeks to provide insights into long-term treatment options for this condition.

Alnylam’s Q2 2025 Earnings Call Highlights Robust Growth

Alnylam Pharmaceuticals’ recent earnings call for Q2 2025 was marked by a positive sentiment, driven by strong revenue growth and successful product launches. Despite some challenges, such as decreased collaboration revenue and increased operating expenses, the company’s significant achievements and robust financial performance set an optimistic tone for the future.

Alnylam Pharmaceuticals Reports Strong Q2 2025 Growth

Alnylam Pharmaceuticals, Inc., a leader in RNA interference (RNAi) therapeutics, focuses on developing innovative medicines for rare and prevalent diseases, leveraging Nobel Prize-winning science to transform patient care.